

Presentation Quarter 3, 2026

October 22, 2026

Ulrika Kolsrud

President and CEO



Highlights Q3 2026

- Resilient performance in a challenging market
- Ongoing price adjustments, sequentially higher prices
- Saving programs delivering
- Acquisition of feminine care business in Brazil
- Consumer Tissue strategic review proceeding according to plan

Organic sales growth

-0.3%

EBITA excl. IAC

SEK
4,725m

EBITA margin
excl. IAC

13.1%

Operating cash flow

SEK
5,783m

Health & Medical

Q3 2026

- Higher prices and stable volumes
- Growth in both Incontinence Products and Medical Solutions
- Expanded compression garment offering with JOBST® Elvarex® Soft Ready-to-Wear



Personal Care

Q3 2026

- Strong volume-driven growth in Incontinence Products and Feminine Care
- Market share gains for branded sales across categories
- Continued roll-out of SmartProtect™ technology
- High growth in North America and Latin America



Acquisition strengthening Essity's feminine care position in Latin America

- Acquiring the market leading brand Carefree, Sempre Livre and o.b. in Brazil
- Approx. SEK 1.4bn¹⁾ in net sales, with good profitability
- Purchase price of USD 284m, expected closing in Q2 2027
- Supports the strategy to grow in Essity's most value-creating categories in attractive markets

¹⁾ BRL 800m; for the twelve-month period ending June 30, 2026



High activity in Personal Care North America

- Integrating Feminine Care acquisition in North America
- Implementing new go to market in US
- TENA online market share in US continuing to grow



Consumer Tissue

Q3 2026

- Sales decline driven by volume and price
- Manufacturing footprint optimization in Latin America
- Margins impacted by previous price reductions and increased cost headwinds
- Ongoing price adjustments, with sequentially higher prices



Professional Hygiene

Q3 2026


- Continued growth of premium products
- Lower volumes driven by base assortment
- Tork Vision Cleaning gaining traction across the globe

Fredrik Rystedt

Executive Vice President
and CFO




Stable volumes and positive impact from acquisition



Organic sales growth:	-0.3%
Health & Medical	+1.2%
• Incontinence Health Care	+1.5%
• Medical Solutions	+0.7%
Personal Care	+3.2%
• Incontinence Retail	+5.1%
• Feminine Care	+5.6%
• Baby Care	-3.9%
Consumer Tissue	-3.0%
Professional Hygiene	-1.1%

Resilient EBITA margin excl. IAC



EBITA margin excl. IAC: 13.1%


Health & Medical	18.4%
Personal Care	13.5%
Consumer Tissue	8.6%
Professional Hygiene	17.0%

Items affecting comparability

> Restructuring costs SG&A savings program	SEK ~450m
> Restructuring costs Consumer Tissue manufacturing footprint optimization in Latin America	SEK ~500m
> Other, including M&A costs	SEK ~140m
> Total IAC Q3	SEK 1 089m


Strong operating cash flow

SEKbn



Strong balance sheet

SEKbn



- + Cash flow
- + IFRS revaluation of pension assets and obligations
- Acquisition
- Dividends and share buybacks
- Other, including currency

Ulrika Kolsrud

President and CEO



Summary

- Q3 2026 – stable volumes, resilient profitability and strong cash flow
- Priorities:
 - Compensate higher input costs with price, while growing market shares
 - Successful execution of initiatives
 - SG&A and COGS saving programs
 - Integration of Feminine Care acquisitions
 - Consumer Tissue strategic review
 - Drive further actions to accelerate profitable growth

This presentation may contain forward-looking statements. Such statements are based on our current expectations and are subject to certain risks and uncertainties that could negatively affect our business. Please read our most recent annual report for a better understanding of these risks and uncertainties.



Q&A

Investor Relations

Contacts



Sandra Åberg
Vice President Investor Relations
sandra.aberg@essity.com
+46 70 564 96 89



Viveca Dominguez
Director Investor Relations
viveca.dominguez@essity.com
+46 70 278 51 52



Janet Östergren
Investor Relations Officer
janet.ostergren@essity.com
+46 70 310 13 74

